non-alcoholic fatty liver disease
Conditions
Interventions
Ezetimibe
control
Sponsors
Eishiro Mizukoshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) NAFLD in histology 2) dyslipidemia TC 220mg/dl or higher or treatment to dyslipidemia has already been done. 3) Case it is possible to take ezetimibe about six months 4) Child-Pugh A 5) 20-80 years old age when registering 6) Performance status(ECOG scale) is 0 or 1 7) Key organ function is maintained by clinical examination within 14 days before it registers.
Exclusion criteria
Exclusion criteria: Patients will be excluded from the study if they meet any of the following criteria: 1)hepatic virus infections (hepatitis B and C) 2)the current or past consumption of more than 20 g of alcohol daily 3)concurrent hepatocellular carcinoma, as determined by diagnostic imaging results 4) hepatic encephalopathy 5) active infections 6) severe complication 7) Woman who has possibility of pregnancy or pregnancy or while suckling. 8)Case to whom medicine in which it is using together taboo of ezetimibe and describes attention of using together is administered 9) those who are inadequate for this study as assessed by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical parameters and liver histologyin NAFLD were evaluated before and after the treatment | — |
Countries
Japan
Contacts
Public ContactEishiro Mizukoshi
Kananzawa University Graduate School of Medical Science Department of Disease Control and Homeostasis
Outcome results
None listed